SVA [SINOVAC BIOTECH] 6-K: (Original Filing)

[Sinovac Reports Unaudited Fourth Quarter 2019 Financial Results and Files 2019 Annual Report on Form 20-F Fourth Quarter and Full Year 2019 Financial Summary Ÿ Sales for the fourth quarter of 2019 were $81.1 million, an increase of 52.4% from $53.2 million in the prior year period. Ÿ Sales in 2019 w]

By | 2020-10-01T15:39:05+00:00 April 30th, 2020|Categories: Chinese Stocks, SEC Original, SVA|Tags: , , , , , |0 Comments

SVA [SINOVAC BIOTECH] 6-K: Sinovac Reports Unaudited Fourth Quarter 2019 Financial Results

[Sinovac Reports Unaudited Fourth Quarter 2019 Financial Results and Files 2019 Annual Report on Form 20-F Fourth Quarter and Full Year 2019 Financial Summary Ÿ Sales for the fourth quarter of 2019 were $81.1 million, an increase of 52.4% from $53.2 million in the prior year period. Ÿ Sales in 2019 w]

By | 2020-10-01T15:39:09+00:00 April 30th, 2020|Categories: Chinese Stocks, SVA, Webplus ver|Tags: , , , , , |0 Comments

SVA [SINOVAC BIOTECH] 20-F: (Original Filing)

[CONTENTS] [SPECIMEN * NOT VALID UNLESS COUNTERSIGNED BY TRANSFER AGENT * INCORPORATED UNDER THE LAWS OF THE GOVERNMENT OF ANTIGUA Number Sinovac Shares BIOTECH LTD. This Certifies that Is the Owner of Fully paid and non-assessable shares of Common Stock of Sinovac Biotech Ltd. transferable on the bo]

By | 2020-10-01T15:39:43+00:00 April 30th, 2020|Categories: Chinese Stocks, SEC Original, SVA|Tags: , , , , , |0 Comments

SVA [SINOVAC BIOTECH] 20-F: CONTENTS

[CONTENTS] [SPECIMEN * NOT VALID UNLESS COUNTERSIGNED BY TRANSFER AGENT * INCORPORATED UNDER THE LAWS OF THE GOVERNMENT OF ANTIGUA Number Sinovac Shares BIOTECH LTD. This Certifies that Is the Owner of Fully paid and non-assessable shares of Common Stock of Sinovac Biotech Ltd. transferable on the bo]

By | 2020-10-01T15:39:46+00:00 April 30th, 2020|Categories: Chinese Stocks, SVA, Webplus ver|Tags: , , , , , |0 Comments

SVA [SINOVAC BIOTECH] 6-K: (Original Filing)

[Sinovac Announces Commencement of Phase I Human Clinical Trial for Vaccine Candidate Against COVID-19 BEIJING --(BUSINESS WIRE)-- April 17, 2020-- Sinovac Biotech Ltd. (NASDAQ:SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that the Compa]

By | 2020-10-01T15:39:56+00:00 April 17th, 2020|Categories: Chinese Stocks, SEC Original, SVA|Tags: , , , , , |0 Comments

SVA [SINOVAC BIOTECH] 6-K: Sinovac Announces Commencement of Phase I Human Clinical

[Sinovac Announces Commencement of Phase I Human Clinical Trial for Vaccine Candidate Against COVID-19 BEIJING --(BUSINESS WIRE)-- April 17, 2020-- Sinovac Biotech Ltd. (NASDAQ:SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that the Compa]

By | 2020-10-01T15:40:00+00:00 April 17th, 2020|Categories: Chinese Stocks, SVA, Webplus ver|Tags: , , , , , |0 Comments

SVA [SINOVAC BIOTECH] 6-K: (Original Filing)

[Sinovac Announces Approval of Human Clinical Trial for a Vaccine Candidate Against COVID-19 BEIJING--(BUSINESS WIRE)-- April 14, 2020-- Sinovac Biotech Ltd. (NASDAQ:SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that the Company has obta]

By | 2020-10-01T15:40:08+00:00 April 14th, 2020|Categories: Chinese Stocks, SEC Original, SVA|Tags: , , , , , |0 Comments

SVA [SINOVAC BIOTECH] 6-K: Sinovac Announces Approval of Human Clinical Trial for

[Sinovac Announces Approval of Human Clinical Trial for a Vaccine Candidate Against COVID-19 BEIJING--(BUSINESS WIRE)-- April 14, 2020-- Sinovac Biotech Ltd. (NASDAQ:SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that the Company has obta]

By | 2020-10-01T15:40:12+00:00 April 14th, 2020|Categories: Chinese Stocks, SVA, Webplus ver|Tags: , , , , , |0 Comments

CPHI [CHINA PHARMA] 10-K: (Original Filing)

[] [Loans Extension Confirmation Letter Reference is made to the loans from Ms. Heung Mei Tsui to China Pharma Holdings, Inc. (the “Company”), the principal and accumulated interest totaled USD1,354,567 and USD111,940.95 respectively as of December 31, 2019. Due to the fact the Company temporarily di]

By | 2020-10-01T10:13:35+00:00 March 30th, 2020|Categories: Chinese Stocks, CPHI, SEC Original|Tags: , , , , , |0 Comments

CPHI [CHINA PHARMA] 10-K:

[] [Loans Extension Confirmation Letter Reference is made to the loans from Ms. Heung Mei Tsui to China Pharma Holdings, Inc. (the “Company”), the principal and accumulated interest totaled USD1,354,567 and USD111,940.95 respectively as of December 31, 2019. Due to the fact the Company temporarily di]

By | 2020-10-01T10:13:39+00:00 March 30th, 2020|Categories: Chinese Stocks, CPHI, Webplus ver|Tags: , , , , , |0 Comments
Skip to toolbar